What is GDTC's current stock price?

GDTC (CytoMed Therapeutics Limited) is currently trading at $1.13 with a market cap of $13.4M.

What sector is CytoMed Therapeutics Limited in?

CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

GDTC CytoMed Therapeutics Limited

Healthcare

$1.13-7.38%ClosedMarket Cap: $13.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.04

P/S

31.38

EV/EBITDA

-2.75

DCF Value

$0.05

FCF Yield

-39.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

-64.0%

Operating Margin

-1075.1%

Net Margin

-1062.1%

ROE

-75.3%

ROA

-56.7%

ROIC

-62.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$167.9K	$-1.7M	$—
FY null	$319.2K	$-3.9M	$—
Q2 null	$105.7K	$-882.3K	$—
Q1 null	$100.0K	$-835.0K	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Yew Chak Huadirector

SellFri May 15

TAN YOONG YINGofficer: Chief Corporate Officer

SellFri May 15

Leong Mark Kei Weidirector:

SellFri May 15

Goh Yvonneofficer: Chief Financial Officer

SellFri May 15

Choo Chee Kongdirector, 10 percent owner:

SellFri May 15

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.17

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Peers